Article Details

Vigil Neuroscience reports interim Phase 2 data for ALSP drug candidate - Seeking Alpha

Retrieved on: 2023-11-16 22:44:29

Tags for this article:

Click the tags to see associated articles and topics

Vigil Neuroscience reports interim Phase 2 data for ALSP drug candidate - Seeking Alpha. View article details on hiswai:

Excerpt

Vigil Neuroscience (VIGL) reported interim Phase 2 results for its drug candidate iluzanebart for the treatment of the rare neurological disease ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up